SavedAdd your journal

Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2012 / Cilt: 58 - Sayı: 1

Osteoporozlu kadınlarda raloksifen tedavisinin antioksidan ve antiinflamatuvar etkilerininin VKİ ve menopoz süresi ile ilişkisi

Relation of BMI and postmenopausal duration with antioxidant and anti-ınflammatory effects of raloxifene treatment in women with osteoporosis: a preliminary report

Yasemin AKÇAY
Bilal İLANBEY
Sibel EYİGÖR
Yeşim KİRAZLI
Eser SÖZMEN
Muammer KARADENİZ
Pages
29–35
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: IL-6 level was significantly decreased but IL-10 and PON1 levels were significantly increased after the study treatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We have not identified any objective evidence in the literature about the effects of raloxifene treatment on the antioxidant and antiinflammatory markers.
📊
Key Findings & Data:Raloxifene hydrochloride 60 mg/day was administered for 6 months.
💡
Conclusion & Impact:Results: IL-6 level was significantly decreased but IL-10 and PON1 levels were significantly increased after the study treatment (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We have not identified any objective evidence in the literature about the effects of raloxifene treatment on the antioxidant and antiinflammatory markers. We investigated the antioxidant/anti-inflammatory effects of raloxifene and the association of its antioxidant/antiinflammatory effects with body mass index (BMI) and postmenopausal period in women with osteoporosis (OP). Materials and Methods: Fourteen postmenopausal women with OP were enrolled in this study. Raloxifene hydrochloride 60 mg/day was administered for 6 months. The oxidant/antioxidant state was evaluated by measuring erythrocyte catalase (e-CAT) and paraoxonase (PON1) activities, levels of thiobarbituric acid (e-TBARS), serum diene, total antioxidant activity (AOA), trolox equivalent antioxidant capacity (TEAC), ferric reducing ability of plasma (FRAP) and anti-inflammatory effects were assessed by measuring tumor necrosis factor (TNF)-α, Interleukin (IL-6), IL-18, IL-10 and adiponectin levels. Plasma cytokine (TNF-alpha, IL-6, IL-10, IL-18) levels were measured by ELISA kits and antioxidant parameters were determined by spectrophotometry. Serum levels of all parameters were measured at baseline and end of the study. Results: IL-6 level was significantly decreased but IL-10 and PON1 levels were significantly increased after the study treatment (p

Özet

Amaç: Literatürde, raloksifen tedavisinin antioksidan ve antiinflamatuvar belirteçler üzerine olan etkileri ile ilişkili yeterli veri olmaması nedeniyle, çalışmamızda hem raloksifenin antioksidan ve antiinflamatuar etkilerini hem de osteoporozlu kadınlarda raloksifenin bu etkilerinin, vücut kütle indeksi (VKİ) ve menopoz süresi ile olan ilişkisini araştırdık. Gereç ve Yöntem: Osteoporozlu 14 kadın çalışmaya dahil edildi. 60 mg/gün olacak şekilde 6 ay boyunca raloksifen hidroklorid verildi. Oksidan/antioksidan durum eritrosit katalaz (e-CAT) ve paraoksonaz aktiviteleri, eritrosit tiyobarbitürik asid (e-TBARS), serum dien düzeyleri, total antioksidan aktivite (AOA), trolox eşedeğeri antioksidan aktivite (TEAC), plazma demir indirgeme kapasitesi (FRAP) ölçülerek belirlendi. Antiinflamatuvar etki ise tümor nekrozis factor (TNF-α), interlökin 6 (IL-6), İnterlökin 18 (IL-18), İnterlökin 10 (IL-10) ve adiponiktin düzeyleri ile belirlendi. Plazma sitokin düzeyleri (TNF-α, IL-6, IL-10, IL-18) ELISA kiti ile antioksidan parametreler spektrofotometrik olarak hem çalışmanın başında hemde sonunda ölçüldü. Bulgular: Tedavi sonrası IL-6 düzeyi anlamlı düşük, IL-10 ve PON1 düzeyi anlamlı yüksek olarak saptandı (p

🔖

Cite This Article

AKÇAY, Y., İLANBEY, B., EYİGÖR, S., KİRAZLI, Y., SÖZMEN, E., KARADENİZ, M. (2022). Osteoporozlu kadınlarda raloksifen tedavisinin antioksidan ve antiinflamatuvar etkilerininin VKİ ve menopoz süresi ile ilişkisi. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 58 - Sayı: 1, 29–35. https://ajindex.com/articles/628907

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993;260:626-7
  2. Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle PF, Collette J, et al. Increase in cytokine production (IL-1b, IL-6, TNF-alpha, but not IFN-c, GMCSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 1997;26:63-71
  3. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, et al. Metaanalyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39
  4. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women: three-year data from two double-blind, randomized, placebo controlled trials. Arch Intern Med 2000;160:3444-50
  5. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
  6. Manolagas SC, Jilka RL. Mechanisms of disease: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11
  7. Méndez-Dávila C, García-Moreno C, Turbì C, de la Piedra C. Effects of 17 beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth Factor-beta1 and insulinlike growth factor-1 in pimary human osteoblast cultures. J Endocrinol Invest 2004;27:904-12
  8. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997;51:535-41
  9. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygenderived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990;85:632-9
  10. Young IS, Woodside JV. Antioxidant in health and disease. J Clin Pathol 2001;54:176-86
  11. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone forming cells. Bone 2004;35:842-9
  12. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N. Protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 2005;54:194-9
  13. Consen